Bayer AG has hit the acquisition trail again, having just agreed to buy the UK's KaNDy Therapeutics Ltd., and a number of other deals are in the pipeline following a revamp of its partnering activities.
Key to the revamp is Marianne De Backer, head of pharmaceuticals business development (BD) and licensing at Bayer, who joined...








